Fed. Circ. Backs Sanofi, Regeneron PTAB Win Over Amgen
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating an Amgen unit's patent on treating inflammatory disorders, in a win for Sanofi and Regeneron, whose eczema...To view the full article, register now.
Already a subscriber? Click here to view full article